69441-18-5

Basic information

• Product Name: 2-[benzyl(methyl)amino]ethyl methyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)pyridine-3,5-dicarboxylate hydrochloride
• Synonyms: 2-[benzyl(methyl)amino]ethyl methyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)pyridine-3,5-dicarboxylate hydrochloride;1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 3-[2-(methylbenzylamino)ethyl]5-methyl/hydrochloric acid,(1:x)
• CAS NO: 69441-18-5
• Molecular Formula: C₂₆H₂₉N₃O₆*ClH
• Molecular Weight: 515.9859
• EINECS: 274-007-4
• Mol File: 69441-18-5.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-[benzyl(methyl)amino]ethyl methyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)pyridine-3,5-dicarboxylate hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[benzyl(methyl)amino]ethyl methyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)pyridine-3,5-dicarboxylate hydrochloride(69441-18-5)
• EPA Substance Registry System: 2-[benzyl(methyl)amino]ethyl methyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)pyridine-3,5-dicarboxylate hydrochloride(69441-18-5)

Safety Data

• Hazardous Substances Data: 69441-18-5(Hazardous Substances Data)

Usage

Main Properties

1. Pyridine Ring: Contains a pyridine ring.
2. Nitro Group: Presence of a nitro group (-NO2) attached to the pyridine ring.
3. Methyl Substituents: Two methyl groups (-CH3) attached to positions 2 and 6 of the pyridine ring.
4. Ester Group: Contains an ester group (-COOCH3).
5. Amine Group: Contains an amine group (-NH2) with benzyl and methyl groups attached to the nitrogen atom.
6. Hydrochloride Salt: Presented in the form of a hydrochloride salt.

Specific Content

Pyridine Ring: Provides aromaticity and potentially serves as a site for chemical reactions.
Nitro Group: Often associated with pharmacological activity, indicating potential pharmaceutical applications.
Methyl Substituents: May influence the compound's reactivity and physical properties.
Ester Group: Can participate in esterification reactions or serve as a site for hydrolysis.
Amine Group: Offers basicity and potential for protonation in acidic conditions, influencing solubility and reactivity.
Hydrochloride Salt Form: Enhances water solubility, facilitating its use in experimental settings and pharmaceutical formulations.

Potential Applications

Pharmaceutical: Due to the presence of the nitro group and complex structure.
Research: Offers opportunities for studying chemical reactions, pharmacological properties, and potential drug development.

Overall Impression

Exhibits a complex and unique chemical structure with potential applications in pharmaceuticals and research due to its intricate composition and the presence of functional groups known for their pharmacological relevance.

Upstream product

• 99-61-6 3-nitro-benzaldehyde 
• 14205-39-1 methyl 3-aminocrotonate 
• 101-98-4 2-(N-benzyl-N-methyl)amino-1-ethanol 
• 54527-65-0 acetoacetic acid [2-(N-methyl-N-benzylamino)-ethyl]-ester 
• 14205-39-1 methyl (E)-3-aminocrotonate 
• 39562-17-9 methyl 2-(3-nitrophenylmethylene)acetoacetate 
• 54527-73-0 2-(N-benzyl-N-methylamino)-ethyl 3-aminocrotonate 
• 85677-95-8 2-hydroxyethyl methyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate 
• 103785-47-3 methanesulfonyloxyethyl methyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate 
• 103-67-3 benzyl-methyl-amine 

Downstream Products

• 101-98-4 2-(N-benzyl-N-methyl)amino-1-ethanol 
• 1259327-68-8 C₁₆H₁₅N₂O₆^(1-)*Na⁽¹⁺⁾ 
• 69441-29-8 2,6-Dimethyl-4-(3-nitro-phenyl)-pyridine-3,5-dicarboxylic acid 3-[2-(benzyl-methyl-amino)-ethyl] ester 5-methyl ester; hydrochloride 

Relevant articles and documents

METHODS FOR TREATING CHRONIC FATIGUE SYNDROME AND MYALGIC ENCEPHALOMYELITIS

In one aspect the invention relates to a method of treatment selected from the group consisting of: (a) treating a symptom such as pain in a subject identified or diagnosed as having Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS); (b) treating a symptom such as pain in a subject having dysfunctional TRPM3 ion channel activity; (c) restoring NK cell function in a subject having dysfunctional TRPM3 ion channel activity; and (d) restoring calcium homeostasis in a subject having dysfunctional TRPM3 ion channel activity. The method comprises the step of administering to the subject a therapeutically effective amount of at least one therapeutic compound selected from the group consisting of: (i) an opioid receptor antagonist; (ii) an opioid antagonist; and (iii) a therapeutic compound that restores TRPM3 ion channel activity. In some embodiments the therapeutic compound is naltrexone hydrochloride.

Processes of manufacturing substituted-1,4-dihydropyridines, improved aqueous solutions thereof, and processes of manufacturing the solutions

A process of preparing a stable parenteral solution of a 1,4-dihydropyridine salt, such as nicardipine hydrochloride, in an acidic aqueous medium. The presence of L-arginine in the solution enhances the solubility of the salt, which is poorly soluble in water. An aqueous, injectable isotonic solution at pH about 3.5-3.6 consists essentially of nicardipine hydrochloride, L-arginine, and a sugar alcohol. An improved single pot manufacturing process for obtaining unsymmetrical 1,4-dihydropyridines by using more than one mole equivalent of aldehyde with respect to the other reactants (amino crotonate and acetoacetate ester). The reaction can be conducted in a solvent present at 20 times the amount of any one component. A process for changing one polymorph of nicardipine hydrochloride (Form A) into another (Form B), and a separate process for the reverse (Form B into Form A).

Inclusion complex of nicardipine or its hydrochloride with beta-cyclodextrin, a process for preparing the same and a sustained release pharmaceutical preparation containing the same

There is described a new inclusion complex of nicardipine or its hydrochloride with beta-cyclodextrin, which is prepared by admixing nicardipine or its hydrochloride with beta--cyclodextrin in a molar ratio of the compounds 1:0.9-1.1 under stirring at a temperature from about room temperature to the boiling temprature of the reaction mixture in an aqueous or ethanolic medium, cooling the reaction mixture to 0 ° to 5 °C and isolating the desired complex. The inclusion complex of nicardipine or its hydrochloride pos-sesses cerebrovascular-vasodilatory and coronary-vasodilatory properties, which are equally well expressed as those of nicar-dipine or its hydrochloride themselves, yet owing to the better solubility of the complex at a higher pH range, such as it ex-ists e.g. in the intestinal tract, the manufacture of sustained release pharmaceutical forms is made possible, whereby a greater extent of dissolution of the active substance is provided also in the intestinal juice.